Inventiva S.A. (IVA)
| Market Cap | 881.34M +90.1% |
| Revenue (ttm) | 7.94M -52.0% |
| Net Income | -415.80M |
| EPS | -2.23 |
| Shares Out | 207.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,919,228 |
| Open | 3.975 |
| Previous Close | 4.040 |
| Day's Range | 3.975 - 4.490 |
| 52-Week Range | 2.854 - 7.983 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 15.13 (+257.68%) |
| Earnings Date | Mar 30, 2026 |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is $15.13, which is an increase of 257.68% from the latest price.
News
Inventiva Transcript: Jefferies Global Healthcare Conference 2026
A recapitalized, single-asset company is advancing lanifibranor for F2/F3 MASH, with phase III top-line data expected in Q4 2024 and a commercial launch targeted for 2028. The product is positioned to compete strongly in diabetic and fibrosis-driven segments.
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva files automatic mixed securities shelf
06:12 EDT Inventiva (IVA) files automatic mixed securities shelf
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Reports 2026 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...
Inventiva to Present Abstracts at the EASL Congress 2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Inventiva CFO Jean Volatier to switch roles, Axel-Sven Malkomes to succeed
Inventiva (IVA) announced three new members of its leadership team: Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. Former CFO Jean…
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization. Axel-Sven Malkome...
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva price target lowered to $15 from $17 at Stifel
Stifel lowered the firm’s price target on Inventiva (IVA) to $15 from $17 and keeps a Buy rating on the shares. The firm notes the company is in final stretches…
Inventiva Earnings Call Transcript: Q4 2025
Inventiva completed NATiV3 phase III enrollment for lanifibranor in MASH, expects top-line data in Q4 2026, and is well-funded through key milestones. Strategic focus, leadership expansion, and divestment of odiparcil position the company for regulatory and commercial readiness.
Inventiva Annual report: Q4 2025
Inventiva has published its Q4 2025 annual report on March 31, 2026.
Inventiva Earnings release: Q4 2025
Inventiva released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q4 2025
Inventiva released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Inventiva Annual report: Q4 2025
Inventiva has published its Q4 2025 annual report on March 31, 2026.
Inventiva reports 2025 full year results and provides a business update
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva management to meet with Piper Sandler
Meeting to be held in Boston on April 2 hosted by Piper Sandler.
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva initiated with a Buy at Truist
Truist initiated coverage of Inventiva (IVA) with a Buy rating and $13 price target Lead asset lanifibranor has a unique mechanism and profile among metabolic dysfunction-associated steatohepatitis th...
Inventiva Transcript: Barclays 28th Annual Global Healthcare Conference
Lanifibranor's Phase III trial for MASH is well-powered and builds on strong Phase IIb results, targeting F2/F3 patients with a favorable safety profile and differentiated market positioning. The company plans independent commercialization, with a cash runway through Q3 2027.
Inventiva Transcript: Leerink Global Healthcare Conference 2026
Lanifibranor's phase 3 data for MASH is expected in late 2024, with strong phase 2b efficacy and a favorable safety profile. The program targets F2/F3 patients, especially diabetics, and plans for commercial launch and expanded indications are underway.